US 11,744,853 B2
Method of administration and treatment
Ryan Beal, Thousand Oaks, CA (US)
Assigned to Dyve Biosciences, Inc., Camarillo, CA (US)
Filed by Dyve Biosciences, Inc., Thousand Oaks, CA (US)
Filed on Oct. 29, 2021, as Appl. No. 17/514,653.
Application 16/866,466 is a division of application No. 16/546,256, filed on Aug. 20, 2019, granted, now 10,639,326, issued on May 5, 2020.
Application 16/546,256 is a division of application No. 16/132,358, filed on Sep. 14, 2018, abandoned.
Application 16/132,358 is a division of application No. 16/132,357, filed on Sep. 14, 2018, abandoned.
Application 17/514,653 is a continuation of application No. 17/488,143, filed on Sep. 28, 2021, abandoned.
Application 17/488,143 is a continuation of application No. 17/168,114, filed on Feb. 4, 2021.
Application 17/168,114 is a continuation of application No. 16/866,466, filed on May 4, 2020, granted, now 10,933,088, issued on Mar. 2, 2021.
Application 16/132,358 is a continuation in part of application No. PCT/US2018/028017, filed on Apr. 17, 2018.
Claims priority of provisional application 62/639,904, filed on Mar. 7, 2018.
Claims priority of provisional application 62/609,982, filed on Dec. 22, 2017.
Claims priority of provisional application 62/562,725, filed on Sep. 25, 2017.
Claims priority of provisional application 62/559,947, filed on Sep. 18, 2017.
Claims priority of provisional application 62/559,360, filed on Sep. 15, 2017.
Prior Publication US 2022/0047624 A1, Feb. 17, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 33/00 (2006.01); A61K 31/198 (2006.01); A61K 31/4172 (2006.01); A61K 31/133 (2006.01); A61K 9/00 (2006.01); A61K 35/00 (2006.01); A61K 9/16 (2006.01); A61K 33/42 (2006.01); A61P 35/04 (2006.01); A61K 31/704 (2006.01); A61K 39/395 (2006.01); A61K 31/661 (2006.01); A61K 9/06 (2006.01); A61K 31/045 (2006.01); A61K 31/685 (2006.01); A61K 33/30 (2006.01); C07K 16/28 (2006.01); A61K 9/70 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/12 (2006.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01); A61K 47/24 (2006.01); A61K 39/00 (2006.01)
CPC A61K 33/00 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 9/16 (2013.01); A61K 9/7023 (2013.01); A61K 31/045 (2013.01); A61K 31/133 (2013.01); A61K 31/198 (2013.01); A61K 31/4172 (2013.01); A61K 31/661 (2013.01); A61K 31/685 (2013.01); A61K 31/704 (2013.01); A61K 33/30 (2013.01); A61K 33/42 (2013.01); A61K 35/00 (2013.01); A61K 39/3955 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/22 (2013.01); A61K 47/24 (2013.01); A61P 35/04 (2018.01); C07K 16/2818 (2013.01); A61K 2039/505 (2013.01); C07K 2317/76 (2013.01)] 20 Claims
 
1. A method for treating rheumatoid arthritis or reducing a symptom of rheumatoid arthritis, the method comprising steps of:
(1) identifying a subject having rheumatoid arthritis or having a symptom thereof; and
(2) topically administering to the identified subject a transdermal formulation,
wherein the transdermal formulation comprises a penetrant or a penetration enhancer and an amount of one or more buffering agents that is effective in treating rheumatoid arthritis or reducing a symptom thereof, and
wherein the one or more buffering agents are selected from sodium bicarbonate, sodium carbonate, a carbonate salt, a bicarbonate salt, a phosphate buffer, TRIS, and lysine
wherein the amount of the one or more buffering agents that is effective in treating rheumatoid arthritis or reducing a symptom thereof is from about 10% to about 56% w/w relative to the formulation.